Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.
Repositioning old drugs can significantly decrease the time and effort that it takes to develop novel antifungal therapeutics, which represents a pressing and unmet clinical need due to the devastating nature of fungal infections. We have previously described the activity of auranofin, a gold thiol compound used to treat rheumatoid arthritis, against Candida albicans biofilms. Here we evaluate its antifungal spectrum of action and describe its activity against a variety of medically important fungi.
a Department of Pathology , The University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.|b Department of Medicine , Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.
Nathan P
NP
Wiederhold
b Department of Medicine , Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.|c South Texas Veterans Health Care System , San Antonio , TX , USA.
Thomas F
TF
Patterson
d Department of Biomedical Engineering , University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.|e South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio , San Antonio , TX , USA.
Anand
A
Srinivasan
e South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio , San Antonio , TX , USA.|f Department of Biology , University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.
Ashok K
AK
Chaturvedi
a Department of Pathology , The University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.
Annette W
AW
Fothergill
e South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio , San Antonio , TX , USA.|f Department of Biology , University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.
Floyd L
FL
Wormley
d Department of Biomedical Engineering , University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.|e South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio , San Antonio , TX , USA.
Anand K
AK
Ramasubramanian
e South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio , San Antonio , TX , USA.|f Department of Biology , University of Texas Health Science Center at San Antonio , San Antonio , TX , USA.
José L
JL
Lopez-Ribot
D000935:Antifungal Agents / Q000494:pharmacology*; D018501:Antirheumatic Agents / Q000494:pharmacology*; D001232:Aspergillus fumigatus / Q000187:drug effects; D001310:Auranofin / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects*; D002177:Candidiasis / Q000382:microbiology; D058492:Drug Repositioning; D005658:Fungi / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests
D000935:Antifungal Agents; D018501:Antirheumatic Agents; D001310:Auranofin
antifungal susceptibility; auranofin; repurposing; spectrum of action